[HTML][HTML] A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - Elsevier
Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - EUROPEAN JOURNAL …, 2021 - air.unimi.it
Purpose: Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - hal.science
Purpose: Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - European journal of …, 2021 - dial.uclouvain.be
Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group 2A
(NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human leukocyte …
(NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human leukocyte …
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - European journal of … - pubmed.ncbi.nlm.nih.gov
Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
[引用][C] A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, JP Machiels, C Le Tourneau… - European Journal of …, 2021 - elibrary.ru
[引用][C] A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - cir.nii.ac.jp
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma
of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial | CiNii …
of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial | CiNii …
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - europepmc.org
Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - kclpure.kcl.ac.uk
Purpose: Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - ejcancer.com
Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …